Registry and biobank for neuroimmunological diseases
Official title: Registry for Patients With Antibody-mediated Neuroimmunological Diseases
Run by Charite University, Berlin, Germany · NCT06958341 · Data updated 2026-11-12
This study is trying to see if certain antibodies in the brain are linked to neurological disorders like encephalopathy and psychosis, and how they might affect patients' health.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 2 sites (Berlin, State of Berlin and 1 other locations) |
| Status | Recruiting |
| Started | February 1, 2021 |
| Main results expected | January 1, 2031 |
| Study ends | July 1, 2031 |
| Registry record updated | May 6, 2025 |
| Trial ID | NCT06958341 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals suspected of having neuroimmunological diseases who require a lumbar puncture for diagnosis.
✕Probably not a fit
Patients who do not have a suspected neuroimmunological condition or those who withdraw consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to investigate the prevalence and significance of antineuronal antibodies in patients with various neurological disorders, including encephalopathy and psychosis. It will collect cerebrospinal fluid (CSF) samples and clinical data to explore correlations between these antibodies and conditions like HSV infection and NMDA receptor autoimmunity. The study seeks to determine whether these antibodies are disease-specific or merely a result of inflammation, and to assess the clinical outcomes of patients with these antibodies. By establishing a comprehensive database, the research hopes to enhance understanding of autoimmune encephalitis and related disorders.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients with autoimmune neurological diseases.
How similar studies have gone: Other studies have shown promise in understanding autoimmune encephalitis, but this registry approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision 2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his/her compliance have to allow an extra 2-3 ml of CSF to be collected. 3. Age: all age groups 4. Gender: patients of both sexes will be included Exclusion criteria: \[1\] Withdrawal of consent
Where it's running
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany Recruiting -
Universität Ulm
Ulm, Germany Recruiting
Study contacts
- Principal investigator: Marc Nikolaus, MD — Charite - Universitaetsmedizin Berlin
- Study coordinator: Markus Schuelke, MD
- Email: markus.schuelke@charite.de
- Phone: +49 30 450 566112
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry and natural history of epilepsy-dyskinesia syndromes
This registry will collect health data and biological samples from people of all ages who have a genetic diagnosis of epilepsy-dyskinesia syndromes to see how their genes relate to their movement and seizure symptoms over time.
-
Understanding epilepsy-dyskinesia syndromes in children
This study is trying to learn more about epilepsy-dyskinesia syndromes in children by gathering information from different countries to see how these movement and seizure disorders are related.
-
Wearable lower-limb exoskeleton to stretch legs and improve walking
This research will test a portable wearable exoskeleton to help people with spasticity from spinal cord injury increase leg range of motion and improve walking.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
RAP-219 long-acting injectable safety and PK study in healthy adults
This early study tests RAP-219-LAI in healthy adults to see how it behaves in the body and whether it is safe and tolerable.
-
Why People with Epilepsy Get More Infections
This study tests whether anti-seizure medicines affect immune function and infection risk in people with epilepsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.